{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ETON/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-08T05:51:15.498Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6837,"canonical_name":"Eton Pharmaceuticals, Inc.","cik":"0001710340","uei":null,"lei":null,"duns":null,"ticker":"ETON"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":32,"fda":1},"count":33,"timeline":[{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":15000,"price_per_share":37.5431,"usd_value":563147,"security_title":"Common Stock, par value $0.001 per share","importance":35.5631465},{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":15000,"price_per_share":37.5431,"usd_value":563147,"security_title":"Common Stock, par value $0.001 per share","importance":35.5631465},{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":13315,"price_per_share":37.5431,"usd_value":499886,"security_title":"Common Stock, par value $0.001 per share","importance":35.4998863765},{"ts":"2026-07-14","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":13315,"price_per_share":37.5431,"usd_value":499886,"security_title":"Common Stock, par value $0.001 per share","importance":35.4998863765},{"ts":"2026-07-14","kind":"sec.insider.m","reporter":"BRYNJELSEN SEAN","title":"President & CEO","shares":200000,"price_per_share":1.37,"usd_value":274000,"security_title":"Common Stock","importance":15.274000000000001},{"ts":"2026-07-13","kind":"sec.filing","form_type":"4","title":"4 — Eton Pharmaceuticals, Inc. — 2026-07-13","url_slug":"/sec/cik-0001710340/4/0001437749-26-023440","accession_number":"0001437749-26-023440","importance":30},{"ts":"2026-07-12","kind":"sec.insider.m","reporter":"Krempa David","title":"Chief Business Officer","shares":10000,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-12","kind":"sec.insider.m","reporter":"BRYNJELSEN SEAN","title":"President & CEO","shares":27500,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":20000,"price_per_share":38.3728,"usd_value":767456,"security_title":"Common Stock, par value $0.001 per share","importance":35.767456},{"ts":"2026-07-07","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":6685,"price_per_share":38.3728,"usd_value":256522,"security_title":"Common Stock, par value $0.001 per share","importance":35.256522168},{"ts":"2026-07-07","kind":"sec.filing","form_type":"4","title":"4 — Opaleye Management Inc. — 2026-07-07","url_slug":"/sec/cik-0001595855/4/0001493152-26-032394","accession_number":"0001493152-26-032394","importance":30},{"ts":"2026-07-06","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":10000,"price_per_share":38,"usd_value":380000,"security_title":"Common Stock, par value $0.001 per share","importance":35.38},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":65000,"price_per_share":37.3851,"usd_value":2430032,"security_title":"Common Stock, par value $0.001 per share","importance":37.4300315},{"ts":"2026-07-02","kind":"sec.insider.s","reporter":"Opaleye Management Inc.","title":"","shares":25000,"price_per_share":37.3851,"usd_value":934628,"security_title":"Common Stock, par value $0.001 per share","importance":35.9346275},{"ts":"2026-06-30","kind":"sec.filing","form_type":"4","title":"4 — Eton Pharmaceuticals, Inc. — 2026-06-30","url_slug":"/sec/cik-0001710340/4/0001437749-26-022154","accession_number":"0001437749-26-022154","importance":30},{"ts":"2026-06-26","kind":"sec.form144","reporter":"Gruber James R.","title":"Officer","shares":251818,"usd_value":8990000,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001974078-26-000256","importance":41.798},{"ts":"2026-06-26","kind":"sec.filing","form_type":"144","title":"144 — Eton Pharmaceuticals, Inc. — 2026-06-26","url_slug":"/sec/cik-0001710340/144/0001974078-26-000256","accession_number":"0001974078-26-000256","importance":30},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Gruber James R.","title":"Officer","shares":25000,"usd_value":875251,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001974078-26-000255","importance":40.175050202},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Eton Pharmaceuticals, Inc. — 2026-06-25","url_slug":"/sec/cik-0001710340/144/0001974078-26-000255","accession_number":"0001974078-26-000255","importance":30},{"ts":"2026-06-17","kind":"sec.form144","reporter":"Adams Jennifer McKie","title":"Director","shares":50000,"usd_value":1618500,"security_title":"Common","approx_sale_date":"2026-06-17","accession_number":"0001974078-26-000249","importance":40.3237},{"ts":"2026-06-17","kind":"sec.insider.s","reporter":"Adams Jennifer McKie","title":null,"shares":50000,"price_per_share":32.4759,"usd_value":1623795,"security_title":"Common Stock","importance":36.623795},{"ts":"2026-06-17","kind":"sec.filing","form_type":"144","title":"144 — Eton Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001710340/144/0001974078-26-000249","accession_number":"0001974078-26-000249","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Eton Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001710340/4/0001437749-26-021000","accession_number":"0001437749-26-021000","importance":30},{"ts":"2026-06-17","kind":"sec.insider.m","reporter":"Adams Jennifer McKie","title":null,"shares":50000,"price_per_share":3.78,"usd_value":189000,"security_title":"Common Stock","importance":15.189},{"ts":"2026-06-09","kind":"sec.filing","form_type":"8-K","title":"8-K — Eton Pharmaceuticals, Inc. — 2026-06-09","url_slug":"/sec/cik-0001710340/8-k/0001437749-26-020005","accession_number":"0001437749-26-020005","importance":35},{"ts":"2026-06-02","kind":"sec.form144","reporter":"Gruber James R.","title":"Officer","shares":3117,"usd_value":84163,"security_title":"Common","approx_sale_date":"2026-06-02","accession_number":"0001974078-26-000212","importance":40.016832566},{"ts":"2026-06-02","kind":"sec.filing","form_type":"144","title":"144 — Eton Pharmaceuticals, Inc. — 2026-06-02","url_slug":"/sec/cik-0001710340/144/0001974078-26-000212","accession_number":"0001974078-26-000212","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"3","title":"3 — Eton Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001710340/3/0001437749-26-019051","accession_number":"0001437749-26-019051","importance":30},{"ts":"2026-05-27","kind":"fda.label","reporter":"Eton Pharmaceuticals, Inc.","title":"HEMANGEOL","security_title":"PROPRANOLOL HYDROCHLORIDE","excerpt":"1 INDICATIONS AND USAGE HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring system","accession_number":"4f8341ee-dac6-1ca9-e063-6394a90ac960","route":"ORAL","product_type":"HUMAN PRESCRIPTION DRUG","importance":30},{"ts":"2026-05-19","kind":"sec.filing","form_type":"8-K","title":"8-K — Eton Pharmaceuticals, Inc. — 2026-05-19","url_slug":"/sec/cik-0001710340/8-k/0001437749-26-017799","accession_number":"0001437749-26-017799","importance":35},{"ts":"2026-05-14","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Eton Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001710340/10-q/0001437749-26-017064","accession_number":"0001437749-26-017064","importance":45},{"ts":"2026-05-14","kind":"sec.filing","form_type":"8-K","title":"8-K — Eton Pharmaceuticals, Inc. — 2026-05-14","url_slug":"/sec/cik-0001710340/8-k/0001437749-26-017063","accession_number":"0001437749-26-017063","importance":35},{"ts":"2026-04-27","kind":"sec.filing","form_type":"8-K","title":"8-K — Eton Pharmaceuticals, Inc. — 2026-04-27","url_slug":"/sec/cik-0001710340/8-k/0001437749-26-013369","accession_number":"0001437749-26-013369","importance":35}]}